Stocks Health care NTRA
NASDAQ · Health careNatera, Inc. (NTRA)
Natera, Inc. brought in $2.9B of revenue over the twelve months to September 30, 2026, up 37.4% from a year earlier. It posted a net loss of $164.7M. Operating cash flow minus capital spending left $109.1M of free cash flow in fiscal 2025. At September 30, 2026 it held $1.1B in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Natera, Inc.
- Net worth
- Natera, Inc. has a market value (market cap) of $45B at the latest share price, and shareholders' equity of $1.9B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.3B (+35.9% year on year), with a net loss of $208.2M. Over the 12 months to September 30, 2026: revenue $2.9B, net loss $164.7M.
- Cash flow
- In fiscal 2025 operations brought in $215.3M of cash; after $106.2M of capital spending, free cash flow was $109.1M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Natera, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Natera, Inc. does
Natera provides cell-free DNA testing services for women's health, oncology, and organ health. Its offerings include non-invasive prenatal tests, carrier screenings, hereditary cancer screenings, minimal residual disease monitoring for cancer patients, and donor-derived cell-free DNA tests for kidney and heart transplant recipients. Its shares trade on NASDAQ under the ticker NTRA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.3B | -$208.2M | -$1.52 | $109.1M |
| 2024 | $1.7B | -$190.4M | -$1.53 | $69.2M |
| 2023 | $1.1B | -$434.8M | -$3.78 | -$286.2M |
| 2022 | $820.2M | -$547.8M | -$5.57 | -$479.2M |
| 2021 | $625.5M | -$471.7M | -$5.21 | -$376.3M |
| 2020 | $391M | -$229.7M | -$2.84 | -$202.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NTRA ranks in Health care
Latest SEC filings
What Natera, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 34% to $794M versus the same quarter last year; diluted EPS -$0.42 versus -$0.64.
- November 5, 2026
- November 5, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 38% to $752.8M versus the same quarter last year; diluted EPS -$0.47 versus -$0.74.
- August 6, 2026
- July 6, 2026
- June 16, 2026
What is NTRA worth? A DCF from its reported cash flow
Insider trades
What the people running Natera, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $103.4M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Brophy Michael BurkesCHIEF FINANCIAL OFFICER | Soldpre-planned (10b5-1) | 470 | $184K |
| November 2, 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN, Director | Soldpre-planned (10b5-1) | 17 | $6.6K |
| November 2, 2026 | Rabinowitz MatthewEXECUTIVE CHAIRMAN, Director | Soldpre-planned (10b5-1) | 731 | $292.6K |
| November 2, 2026 | Sheena JonathanDirector | Soldpre-planned (10b5-1) | 3 | $1.2K |
| November 2, 2026 | Sheena JonathanDirector | Soldpre-planned (10b5-1) | 109 | $43.6K |
| November 2, 2026 | Brophy Michael BurkesCHIEF FINANCIAL OFFICER | Soldpre-planned (10b5-1) | 8 | $3.1K |
| November 2, 2026 | Brophy Michael BurkesCHIEF FINANCIAL OFFICER | Soldpre-planned (10b5-1) | 317 | $126.9K |
| November 2, 2026 | Chapman Steven LeonardCEO AND PRESIDENT, Director | Soldpre-planned (10b5-1) | 21 | $8.1K |
Who owns NTRA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 9.5% | November 5, 2026 |
| T. Rowe Price Associates, Inc.13G, passive | 6.3% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.08% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 846 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jpmorgan Chase & Co | 12,865,346 | -521,321 |
| BlackRock, Inc. | 10,914,608 | +237,270 |
| Vanguard Capital Management LLC | 6,228,216 | +219,720 |
| Vanguard Portfolio Management LLC | 5,782,640 | +137,945 |
| Fmr LLC | 5,451,396 | +2,897,142 |
| Wellington Management Group Llp | 4,040,738 | -727,855 |
| State Street Corp | 3,655,618 | +238,146 |
| Geode Capital Management, LLC | 2,750,013 | -25,915 |
| Franklin Resources Inc | 2,725,903 | +240,578 |
| Castle Hook Partners LP | 2,596,276 | +66,466 |
| Coatue Management LLC | 2,505,090 | -36,752 |
| Aqr Capital Management LLC | 2,344,570 | +70,579 |
| Farallon Capital Management, L.L.C. | 2,218,366 | -989,000 |
| Massachusetts Financial Services Co | 1,971,391 | -68,715 |
| Norges Bank | 1,828,122 | new |
| Fred Alger Management, LLC | 1,778,009 | +21,537 |
| Goldman Sachs Group Inc | 1,720,152 | +952,921 |
| Sofinnova Investments, Inc. | 1,550,280 | 0 |
| Capital World Investors | 1,504,387 | +36,412 |
| Arrowstreet Capital, Limited Partnership | 1,503,706 | +311,974 |
Insiders
16 insiders reported holding 4,076,428 shares in total, about $1.27B at the last price.
| Holder | Shares |
|---|---|
| Rabinowitz MatthewEXECUTIVE CHAIRMAN, Director | 2,116,928 |
| Botha RoelofDirector | 1,080,7831,076,198 held indirectly |
| Sheena JonathanDirector | 225,8248,250 held indirectly |
| Fesko JohnPRESIDENT, CHIEF BUS. OFFICER | 195,276 |
| Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER | 167,880 |
| Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | 101,323 |
| Chapman Steven LeonardCEO AND PRESIDENT, Director | 87,431 |
| Brophy Michael BurkesCHIEF FINANCIAL OFFICER | 45,779 |
| Baynes Roy D.Director | 20,158 |
| Marcus Gail BoxerDirector | 7,852 |
Questions about NTRA
What does Natera, Inc. do?
Natera provides cell-free DNA testing services for women's health, oncology, and organ health. Its offerings include non-invasive prenatal tests, carrier screenings, hereditary cancer screenings, minimal residual disease monitoring for cancer patients, and donor-derived cell-free DNA tests for kidney and heart transplant recipients. Its shares trade on NASDAQ under the ticker NTRA.
What is Natera, Inc.'s net worth?
Natera, Inc. has a market value (market cap) of $45B at the latest share price, and shareholders' equity of $1.9B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Natera, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $164.7M on revenue of $2.9B.
How much revenue does Natera, Inc. make?
Over the twelve months to September 30, 2026 Natera, Inc. reported revenue of $2.9B. That is 37.4% more than a year earlier.
When did Natera, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.
When is Natera, Inc.'s next earnings report?
Natera, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NTRA with
Follow NTRA
Get an email when Natera, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Natera, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.